Fecal Calprotectin Test Market Size, Share and Growth Outlook, 2026

Fecal Calprotectin Test Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Fecal Calprotectin Test Market size is forecast to increase from $6.52 Billion in 2026 to $14.6 Billion in 2034 at a CAGR of 10.6% between 2026 and 2034.

The Fecal Calprotectin Test market report provides detailed analysis and outlook of Fecal Calprotectin Test segments including By Assay (Enzyme-Linked Immunosorbent Assay, Enzyme Fluoroimmunoassay, Quantitative & Semi-Quantitative Immunochromatography, Point-of-Care Testing ), By Clinical Indication (Inflammatory Bowel Disease Diagnosis & Monitoring, Irritable Bowel Syndrome, Colorectal Cancer Screening, Celiac Disease Management, Other Gastrointestinal Disorders), By System Modality (Laboratory-Based Automated Testing Systems, Standalone Rapid Testing Kits, Home-Based Patient Self-Testing Platforms ), By End-User (Diagnostic Laboratories & Reference Centers, Hospitals & Inpatient Gastrointestinal Clinics, Academic & Medical Research Institutes, Outpatient Care Facilities & Ambulatory Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Fecal Calprotectin Test Industry Overview

Growing Demand for Non-Invasive Gastrointestinal Diagnostics Drives Market Development

The fecal calprotectin test industry is expanding as healthcare providers increasingly adopt non-invasive diagnostic tools to evaluate gastrointestinal inflammation and support the diagnosis of digestive disorders. Fecal calprotectin testing has become an important component of clinical decision-making for distinguishing inflammatory bowel disease (IBD) from functional gastrointestinal conditions such as irritable bowel syndrome (IBS). Advancements in assay automation, diagnostic accuracy, and laboratory workflow integration are strengthening the role of fecal calprotectin testing within modern gastroenterology practice.

Automated Testing Platforms Advance Diagnostic Efficiency

American Laboratory Products Company, Ltd. (ALPCO) expanded its presence in the fecal calprotectin testing market through the commercial launch of its Calprotectin Immunoturbidimetric Assay across European markets. The company also initiated active patient enrollment in a pivotal U.S. clinical trial evaluating an automated chemiluminescent version of the assay for future FDA submissions. The development of automated testing technologies reflects a growing industry emphasis on improving laboratory efficiency, reducing turnaround times, and supporting broader adoption of fecal calprotectin diagnostics in routine clinical settings.

Multi-Marker Clinical Studies Strengthen Diagnostic Accuracy

Clinical research initiatives continue to enhance the value of fecal calprotectin testing in gastrointestinal disease management. DiaSorin Inc. updated clinical trial activities associated with its COMBI study, a multinational and multicenter investigation evaluating the performance of the upcoming LIAISON® Calprotectin HD system. The study is specifically assessing the test’s ability to differentiate inflammatory bowel disease from irritable bowel syndrome, helping clinicians reduce unnecessary colonoscopy procedures. Such large-scale clinical evaluations demonstrate the industry's commitment to improving diagnostic precision and supporting evidence-based gastrointestinal care pathways.

Regulatory Oversight Reinforces Market Compliance Standards

Regulatory compliance remains a critical factor within the fecal calprotectin test industry. The FDA classified a Class 2 medical device recall involving IBS Test fecal calprotectin distribution kits imported by GetTested International AB. Regulatory action was initiated because the products were distributed within the United States without obtaining the required premarket approval or 510(k) clearance. This development highlights the increasing importance of regulatory adherence, product validation, and quality assurance practices as manufacturers seek to expand access to gastrointestinal diagnostic testing solutions.

Fecal Calprotectin Test Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Fecal Calprotectin Test market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- BÜHLMANN Laboratories AG, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A., Thermo Fisher Scientific Inc., Immundiagnostik AG, R-Biopharm AG, Gentian Diagnostics ASA, ScheBo Biotech AG, Tecan Group Ltd. (IBL International), Bio-Rad Laboratories, Inc.. The Fecal Calprotectin Test market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Fecal Calprotectin Test industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Fecal Calprotectin Test Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Fecal Calprotectin Test companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Fecal Calprotectin Test markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Fecal Calprotectin Test Market Competitive Benchmarking and Company Analysis

Leading companies in Fecal Calprotectin Test industry include- BÜHLMANN Laboratories AG, F. Hoffmann-La Roche Ltd, DiaSorin S.p.A., Thermo Fisher Scientific Inc., Immundiagnostik AG, R-Biopharm AG, Gentian Diagnostics ASA, ScheBo Biotech AG, Tecan Group Ltd. (IBL International), Bio-Rad Laboratories, Inc.. The Fecal Calprotectin Test market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Fecal Calprotectin Test Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Fecal Calprotectin Test market remains one of the strongest-performing segments in the country.
The US Fecal Calprotectin Test Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Fecal Calprotectin Test market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Fecal Calprotectin Test industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Fecal Calprotectin Test markets

Canada's strong Fecal Calprotectin Test sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Fecal Calprotectin Test market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Fecal Calprotectin Test Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Fecal Calprotectin Test market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Fecal Calprotectin Test population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Fecal Calprotectin Test industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Fecal Calprotectin Test market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Fecal Calprotectin Test sales through 2034

France Fecal Calprotectin Test companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Fecal Calprotectin Test Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Fecal Calprotectin Test distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Fecal Calprotectin Test Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Fecal Calprotectin Test market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Fecal Calprotectin Test industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Fecal Calprotectin Test industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Fecal Calprotectin Test Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Fecal Calprotectin Test market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Fecal Calprotectin Test market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Fecal Calprotectin Test Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Fecal Calprotectin Test Market Segmentation

By Assay
Enzyme-Linked Immunosorbent Assay
Enzyme Fluoroimmunoassay
Quantitative & Semi-Quantitative Immunochromatography
Point-of-Care Testing
By Clinical Indication
Inflammatory Bowel Disease Diagnosis & Monitoring
Irritable Bowel Syndrome
Colorectal Cancer Screening
Celiac Disease Management
Other Gastrointestinal Disorders
By System Modality
Laboratory-Based Automated Testing Systems
Standalone Rapid Testing Kits
Home-Based Patient Self-Testing Platforms
By End-User
Diagnostic Laboratories & Reference Centers
Hospitals & Inpatient Gastrointestinal Clinics
Academic & Medical Research Institutes
Outpatient Care Facilities & Ambulatory Centers

Top Companies in Fecal Calprotectin Test Industry

BÜHLMANN Laboratories AG
F. Hoffmann-La Roche Ltd
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Immundiagnostik AG
R-Biopharm AG
Gentian Diagnostics ASA
ScheBo Biotech AG
Tecan Group Ltd. (IBL International)
Bio-Rad Laboratories, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025